Cymabay Therapeutics Inc (NASDAQ:CBAY) saw an upside of 6.42% to $15.24 after adding $0.92 on Tuesday. The 5-day average trading volume is 1,857,288 shares of the company’s common stock. It has gained $15.74 in the past week and touched a new high 1 time within the past 5 days. An average of 3,205,717 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,197,081.
CBAY’s 1-month performance is 15.45% or $2.19 on its low of $13.20 reached on 09/07/23. The company’s shares have touched a 52-week low of $3.15 and high of $18.20, with the stock’s rally to the 52-week high happening on 09/12/23. YTD, CBAY has achieved 143.06% or $9.12 and has reached a new high 35 times. However, the current price is down -16.26% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CBAY stock investors last saw insider trading activity on Sep 18.McWherter Charles (President of R&D) most recently sold 21,746 shares at $16.22 per share on Sep 18. This transaction cost the insider $352,733. General Counsel, Quinlan Paul T, sold 53,000 shares at a price of $16.87 on Sep 15. Then, on Aug 18, President of R&D McWherter Charles sold 21,746 shares at a price of $11.47 per share. This transaction amounted to $249,359.
Valuation Metrics
CBAY stock has a beta of 0.34. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 48.22 while the price-to-book (PB) in the most recent quarter is 13.75.
Cymabay Therapeutics Inc’s quick ratio for the period ended June 29 was 12.52, with the current ratio over the same period at 12.52. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.92, while the total debt to equity was 0.92. In terms of profitability, the gross margin trailing 12 months is 97.49%. The firm’s gross profit as reported stood at $14.91 million against revenue of $93.11 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income shrunk -3244.44% to -$0.81 million, while revenue of -$28.78 million was -3453.09% off the previous quarter. Analysts expected CBAY to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.01, representing a 95.00% surprise. EBITDA for the quarter stood at more than -$1.88 million. CBAY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 118.24 million, with total debt at $99.62 million. Shareholders hold equity totaling $98.15 million.
Let’s look briefly at Cymabay Therapeutics Inc (CBAY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 25 September was 53.88% to suggest the stock is trending Neutral, with historical volatility in this time period at 54.52%.
The stock’s 5-day moving average is $14.73, reflecting a -0.13% or -$0.02 change from its current price. CBAY is currently trading +11.44% above its 20-day SMA, +49.85% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +32.33% and SMA200 by+291.60%.
Stochastic %K and %D was 32.13% and 29.33% and the average true range (ATR) pointed at 0.90. The RSI (14) points at 55.55%, while the 14-day stochastic is at 43.80% with the period’s ATR at 0.90. The stock’s 9-day MACD Oscillator is pointing at -0.58 and -1.00 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Cymabay Therapeutics Inc (NASDAQ: CBAY), UBS launched coverage with a Buy rating. Analysts offering their rating for CBAY stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CBAY as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 13 have offered a “buy” rating.
What is CBAY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $19.00 and a high of $33.00, with their median price target at $22.00. Looking at these predictions, the average price target given by analysts is for Cymabay Therapeutics Inc (CBAY) stock is $22.75.
